Tofacitinib as treatment for refractory dermatomyositis: A retrospective study from 2 academic medical centers

Michelle S Min; Abeer Alsarheed; Bina Kassamali; Daniel R Mazori; Morgan Schaefer; Joseph F Merola; Gabriela Cobos; Avery H LaChance; Ruth Ann Vleugels

doi:10.1016/j.jaad.2021.07.003

Back

$Tofacitinib as treatment for refractory dermatomyositis: A retrospective study from 2 academic medical centers$

Journal article

Peer reviewed

Tofacitinib as treatment for refractory dermatomyositis: A retrospective study from 2 academic medical centers

Michelle S Min, Abeer Alsarheed, Bina Kassamali, Daniel R Mazori, Morgan Schaefer, Joseph F Merola, Gabriela Cobos, Avery H LaChance and Ruth Ann Vleugels

Journal of the American Academy of Dermatology, Vol.86(2), pp.423-425

02/2022

DOI: https://doi.org/10.1016/j.jaad.2021.07.003

PMID: 34246697

Abstract

Academic Medical Centers

Dermatomyositis - drug therapy

Humans

Piperidines - therapeutic use

Pyrimidines

Retrospective Studies

Metrics

1 Record Views

See more details

Details

Title: Tofacitinib as treatment for refractory dermatomyositis: A retrospective study from 2 academic medical centers
Creators - without role: Michelle S Min - Brigham and Women's Hospital
Abeer Alsarheed - King Saud bin Abdulaziz University for Health Sciences
Bina Kassamali - Brigham and Women's Hospital
Daniel R Mazori - Brigham and Women's Hospital
Morgan Schaefer - Brigham and Women's Hospital
Joseph F Merola - Brigham and Women's Hospital
Gabriela Cobos - Brigham and Women's Hospital
Avery H LaChance - Brigham and Women's Hospital
Ruth Ann Vleugels - Brigham and Women's Hospital
Publication Details: Journal of the American Academy of Dermatology, Vol.86(2), pp.423-425
Identifiers: 9921236208331
Academic Unit: King Abdulaziz University
Language: English
Resource Type: Journal article